Skip to content
Inciteful Med

Finding Your Footing: A Parent's Guide to Understanding OI

Last updated:

Osteogenesis imperfecta (OI), or brittle bone disease, is a rare genetic disorder affecting collagen production, causing fragile bones. While life-altering, most children with OI live long, fulfilling lives with the help of treatments like bisphosphonates, physical therapy, and surgical rodding.

Key Takeaways

  • • Osteogenesis imperfecta is a genetic disorder that prevents the body from making strong, properly formed collagen.
  • • Most children with OI, particularly those with mild to moderate types, have a normal life expectancy.
  • • Modern treatments, including bisphosphonates and telescopic surgical rods, can significantly strengthen bones and improve mobility.
  • • OI is a systemic condition that can also affect the teeth, hearing, heart, and lungs, requiring a multidisciplinary care team.
  • • Parents should obtain a formal medical letter confirming the OI diagnosis to prevent misunderstandings about frequent fractures.

Receiving a diagnosis of Osteogenesis Imperfecta (OI)—often called “brittle bone disease”—is a life-altering moment that often follows a period of intense fear and confusion [1]. You may have spent weeks or months watching your child suffer unexplained fractures, or perhaps you have faced the profound trauma of being wrongly accused of child abuse before the true medical cause was found [2][3].

It is normal to feel a mix of overwhelming panic and, paradoxically, a sense of relief that there is finally an answer [1]. This page is designed to help you catch your breath and understand the foundational facts of the journey ahead.

What is Osteogenesis Imperfecta?

At its core, OI is a genetic disorder—meaning it is caused by a change in your child’s DNA [4]. It primarily affects how the body produces collagen, which is the “scaffolding” or “glue” that gives bones their strength and flexibility [5].

  • The Scaffolding Problem: Most cases of OI involve mutations in the COL1A1 or COL1A2 genes [4]. Think of collagen as the rebar inside a concrete pillar. In OI, the body either doesn’t make enough “rebar” (quantitative defect), or the “rebar” it makes is the wrong shape and doesn’t fit together correctly (qualitative defect) [6][7].
  • Bone Fragility: Because the internal scaffolding is weak or missing, the bones become brittle and can break under very little pressure—sometimes even during normal activities like crawling or being diapered [8][9].
  • Incidence: OI is rare, occurring in approximately 1 in 20,000 births [10]. Because of its rarity, many local pediatricians or emergency room doctors may have never treated a child with OI, which is why specialized care is so important [11][12].

Three Stabilizing Facts

In the early days of a diagnosis, it is easy to focus on the limitations. However, modern medicine has significantly changed the outlook for children with OI.

1. Survival is Generally Expected

While OI is a serious condition, most children diagnosed with OI lead long lives [13].

  • Types of OI: Doctors use the Sillence Classification to describe the severity of the disease [14].
  • Mild to Moderate: Children with Type I (the most common and mildest form) often have a near-normal life expectancy [10][15].
  • Lethal Form: There is a specific, very severe form known as Type II, which sadly is often life-limiting shortly after birth due to extreme respiratory issues, but this is a distinct and specific diagnosis [14][13]. For the majority of other types, survival into adulthood is the expectation [12].

2. Powerful Treatments Exist

We are no longer in an era where “wait and see” is the only option. A multidisciplinary approach can significantly strengthen your child’s bones and mobility [16].

  • Bisphosphonates: These are medications (like pamidronate or zoledronic acid) that help increase bone mineral density and reduce the frequency of fractures [17][18].
  • Surgical Rodding: Surgeons can place internal supports called intramedullary rods inside the long bones (like the femurs or humerus) [19]. Specialized “telescopic” rods can even grow along with your child, providing internal strength and helping to prevent future breaks [16][20].
  • Physical Therapy: Specialized therapy is essential to build the muscle strength that helps protect fragile bones [19][21].

3. A Full Life is Possible

A diagnosis of OI does not determine a child’s potential. While they will face physical challenges and chronic pain may be a factor in adulthood, research shows that mental health and social functioning in people with OI are generally comparable to the general population [22][23]. Many individuals with OI pursue higher education, careers, and have families of their own [24][25].

Understanding the “Systemic” Nature

While “brittle bones” is the most famous symptom, OI is a systemic disease, meaning it can affect other parts of the body that rely on collagen [26]. You may hear your doctors mention:

  • Blue Sclera: A bluish tint to the whites of the eyes [27].
  • Dentinogenesis Imperfecta: Brittle or discolored teeth [27].
  • Hearing Loss: Often developing later in childhood or early adulthood [12].
  • Respiratory and Heart Health: Because collagen is in the lungs and heart valves, long-term monitoring by specialists is a standard part of care [28][29].

You are not alone in this. While the diagnosis is heavy, you are now equipped with the information needed to build a team that will support your child’s strength and independence.

Frequently Asked Questions

What causes osteogenesis imperfecta?
Osteogenesis imperfecta is caused by a genetic mutation, most commonly in the COL1A1 or COL1A2 genes. This mutation affects how the body produces collagen, which is the essential protein that gives bones their strength and flexibility.
What is the life expectancy for a child with osteogenesis imperfecta?
Most children diagnosed with osteogenesis imperfecta have a normal life expectancy. While the most severe form, Type II, is often life-limiting shortly after birth, children with mild to moderate types generally survive into adulthood and lead full, independent lives.
How is osteogenesis imperfecta treated?
Treatment involves a multidisciplinary approach to strengthen bones and improve mobility. Common treatments include medications called bisphosphonates to increase bone density, specialized physical therapy, and surgical placement of rods inside the bones to prevent fractures.
Why does my child with OI need to see heart and lung specialists?
Osteogenesis imperfecta is a systemic disease that affects collagen throughout the body, not just in the bones. Because collagen is also found in the lungs and heart valves, your child will need long-term monitoring by specialists to ensure their respiratory and cardiovascular systems stay healthy.
How can I protect my child with OI from accidental fractures?
It is important to learn specific safe handling protocols from your medical team. These protocols cover daily activities like diaper changes, bathing, and car seat use to minimize pressure on fragile bones and prevent accidental breaks.

Questions for Your Doctor

  • • What is my child's specific Sillence type (I, II, III, IV, or V+), and how does that typically affect their long-term outlook?
  • • Do you have a formal letter or medical report confirming the OI diagnosis that we can keep for our records and share with other providers to prevent future misunderstandings about fractures?
  • • How many other children with OI do you currently treat, and are there other specialists (like a pediatric pulmonologist or cardiologist) we should see for a baseline evaluation?
  • • What are the immediate next steps for baseline testing, such as a skeletal survey or a DEXA scan for bone density?
  • • Can you provide us with specific 'safe handling' protocols for things like diaper changes, bathing, and car seat use to help prevent accidental fractures?

Questions for You

  • • How did I feel when I first received the diagnosis—was it a sense of relief to have an answer, or a feeling of overwhelming panic?
  • • Have we experienced any unfair accusations or investigations regarding our child's injuries, and what support do we need to process that trauma?
  • • What are our biggest fears about our child's future, and which of those can we address with the medical team today?
  • • What do we need most right now to feel supported—is it more medical information, connection with other parents, or practical tools for daily care?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Osteogenesis Imperfecta and Child Abuse From a Forensic Point of View.

    Altalib A, Althomali A, Alshahrani A, et al.

    Cureus 2021; (13(1)):e12790 doi:10.7759/cureus.12790.

    PMID: 33628660
  2. 2

    Beware of Osteogenesis Imperfecta: Subdural Hematoma in a 10-Year-Old Child With Minor Head Trauma.

    Dinca EB, Carron R

    The Journal of nervous and mental disease 2019; (207(7)):575-576 doi:10.1097/NMD.0000000000001009.

    PMID: 31259792
  3. 3

    What every clinical geneticist should know about testing for osteogenesis imperfecta in suspected child abuse cases.

    Pepin MG, Byers PH

    American journal of medical genetics. Part C, Seminars in medical genetics 2015; (169(4)):307-13 doi:10.1002/ajmg.c.31459.

    PMID: 26566591
  4. 4

    Structural Variants in COL1A1 and COL1A2 in Osteogenesis Imperfecta.

    Batkovskyte D, Swolin-Eide D, Hammarsjö A, et al.

    American journal of medical genetics. Part A 2025; (197(3)):e63935 doi:10.1002/ajmg.a.63935.

    PMID: 39513464
  5. 5

    Type-I collagen produced by distinct fibroblast lineages reveals specific function during embryogenesis and Osteogenesis Imperfecta.

    Chen Y, Yang S, Lovisa S, et al.

    Nature communications 2021; (12(1)):7199 doi:10.1038/s41467-021-27563-3.

    PMID: 34893625
  6. 6

    Insight into the Pathology of a COL1A1 Signal Peptide Heterozygous Mutation Leading to Severe Osteogenesis Imperfecta.

    Lindert U, Gnoli M, Maioli M, et al.

    Calcified tissue international 2018; (102(3)):373-379 doi:10.1007/s00223-017-0359-z.

    PMID: 29101475
  7. 7

    Health-related quality of life in children with osteogenesis imperfecta: a large-sample study.

    Song Y, Zhao D, Li L, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019; (30(2)):461-468 doi:10.1007/s00198-018-4801-5.

    PMID: 30569229
  8. 8

    Endoplasmic reticulum stress is induced in growth plate hypertrophic chondrocytes in G610C mouse model of osteogenesis imperfecta.

    Scheiber AL, Guess AJ, Kaito T, et al.

    Biochemical and biophysical research communications 2019; (509(1)):235-240 doi:10.1016/j.bbrc.2018.12.111.

    PMID: 30579604
  9. 9

    4-Phenylbutyric acid enhances the mineralization of osteogenesis imperfecta iPSC-derived osteoblasts.

    Takeyari S, Kubota T, Ohata Y, et al.

    The Journal of biological chemistry 2021; (296()):100027 doi:10.1074/jbc.RA120.014709.

    PMID: 33154166
  10. 10

    Osteogenesis Imperfecta and hearing loss in the paediatric population.

    Joseph JK, Maharaj SH

    International journal of pediatric otorhinolaryngology 2021; (150()):110914 doi:10.1016/j.ijporl.2021.110914.

    PMID: 34500359
  11. 11

    Current situation of osteogenesis imperfecta in Spain: results from a Delphi study.

    Sagastizabal B, Calvo I, Martínez-Ferrer À, et al.

    Orphanet journal of rare diseases 2024; (19(1)):239 doi:10.1186/s13023-024-03248-0.

    PMID: 38890698
  12. 12

    [Rehabilitation of orphan diseases in adulthood: osteogenesis imperfecta].

    Gehlen M, Schwarz-Eywill M, Hinz C, et al.

    Zeitschrift fur Rheumatologie 2021; (80(1)):29-42 doi:10.1007/s00393-020-00927-8.

    PMID: 33259008
  13. 13

    Current Overview of Osteogenesis Imperfecta.

    Deguchi M, Tsuji S, Katsura D, et al.

    Medicina (Kaunas, Lithuania) 2021; (57(5)) doi:10.3390/medicina57050464.

    PMID: 34068551
  14. 14

    Osteogenesis Imperfecta Type II: The Lethal Newborn Form Diagnosed in the Postnatal Period.

    Elhaddadi H, Ayyad A, Messaoudi S, Amrani R

    Cureus 2024; (16(5)):e60945 doi:10.7759/cureus.60945.

    PMID: 38910652
  15. 15

    Molecular drivers of osteogenesis imperfecta: a cellular and extracellular collagen disease.

    Cotti S, Pérez Franco W, Forlino A

    Clinical science (London, England : 1979) 2025; (139(24)) doi:10.1042/CS20255642.

    PMID: 41410595
  16. 16

    A Fracture From a Physical Exam: A Case Report of Osteogenesis Imperfecta and the Use of Fassier-Duval Rods.

    Rella RT, Brandon AS, Garrison IA, et al.

    Cureus 2023; (15(4)):e37068 doi:10.7759/cureus.37068.

    PMID: 37153255
  17. 17

    Efficacy and safety of intravenous Zolidronic acid in the treatment of pediatric osteogenesis imperfecta: a systematic review.

    Mahmoud I, Bouden S, Sahli M, et al.

    Journal of pediatric orthopedics. Part B 2024; (33(3)):283-289 doi:10.1097/BPB.0000000000001104.

    PMID: 37339526
  18. 18

    Safety and Efficacy of Zoledronic Acid in children with Osteogenesis Imperfecta.

    Riaz M, Hafeez S, Ibrahim MN, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2022; (32(9)):1165-1169 doi:10.29271/jcpsp.2022.09.1165.

    PMID: 36089714
  19. 19

    Telescopic rodding in children: Technical progression from Dubow-Bailey to Fassier-Duval™.

    Fassier A

    Orthopaedics & traumatology, surgery & research : OTSR 2021; (107(1S)):102759 doi:10.1016/j.otsr.2020.102759.

    PMID: 33316440
  20. 20

    Extendable intramedullary nailing in a child with osteogenesis imperfecta of bilateral femoral fractures: a case report.

    Zhang W, Lu X, Yang N, et al.

    Frontiers in surgery 2025; (12()):1454192 doi:10.3389/fsurg.2025.1454192.

    PMID: 41607377
  21. 21

    Functional Outcome of Humeral Rodding in Children With Osteogenesis Imperfecta.

    Ashby E, Montpetit K, Hamdy RC, Fassier F

    Journal of pediatric orthopedics 2018; (38(1)):49-53 doi:10.1097/BPO.0000000000000729.

    PMID: 26866647
  22. 22

    Initial report of the osteogenesis imperfecta adult natural history initiative.

    Tosi LL, Oetgen ME, Floor MK, et al.

    Orphanet journal of rare diseases 2015; (10()):146 doi:10.1186/s13023-015-0362-2.

    PMID: 26578084
  23. 23

    Systematic review of health related-quality of life in adults with osteogenesis imperfecta.

    Mc Donald D, Mc Donnell T, Martin-Grace J, et al.

    Orphanet journal of rare diseases 2023; (18(1)):36 doi:10.1186/s13023-023-02643-3.

    PMID: 36814291
  24. 24

    Health-related quality of life in individuals with osteogenesis imperfecta in the United States: a cross-sectional study.

    Derocher CE, Mulcrone JE, Carter EM, Raggio CL

    Orphanet journal of rare diseases 2025; (20(1)):537 doi:10.1186/s13023-025-04073-9.

    PMID: 41131612
  25. 25

    Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta.

    Matsushita M, Mishima K, Yamashita S, et al.

    Journal of bone and mineral metabolism 2020; (38(1)):109-116 doi:10.1007/s00774-019-01033-9.

    PMID: 31463628
  26. 26

    Osteogenesis Imperfecta: Skeletal and Non-skeletal Challenges in Adulthood.

    Hald JD, Langdahl B, Folkestad L, et al.

    Calcified tissue international 2024; (115(6)):863-872 doi:10.1007/s00223-024-01236-x.

    PMID: 38836890
  27. 27

    Eight mutations including 5 novel ones in the COL1A1 gene in Czech patients with osteogenesis imperfecta.

    Hruskova L, Fijalkowski I, Van Hul W, et al.

    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2016; (160(3)):442-7 doi:10.5507/bp.2016.022.

    PMID: 27132807
  28. 28

    Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community.

    Swezey T, Reeve BB, Hart TS, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019; (30(2)):507-511 doi:10.1007/s00198-018-4690-7.

    PMID: 30191258
  29. 29

    Cardiac health, type I collagen, and aging in the oim/oim mouse model of osteogenesis imperfecta and a cohort of adults with OI.

    Lafaver BN, Lee L, Derocher CE, et al.

    American journal of physiology. Heart and circulatory physiology 2025; (328(3)):H565-H580 doi:10.1152/ajpheart.00535.2024.

    PMID: 39902996

This page provides educational information about osteogenesis imperfecta for parents and caregivers. It does not replace professional medical advice, diagnosis, or treatment from your child's pediatric specialists.

Stay up to date

Get notified when new research about Osteogenesis imperfecta is published.

No spam. Unsubscribe anytime.